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A summary of HD and non-HD cases is shown in Table 1. Kidney
weights were markedly lower in HD cases than in non-HD cases.
Materials
Standards of o -, m -, and p -cresol were purchased from Wako
Pure Chemical Industries (Tokyo, Japan). The deuterated internal
standard (IS), p -cresol -d8, was obtained from C/D/N Isotopes
Inc. (Quebec, Canada). NaCl, MgSO4, ethyl acetate, acetic anhy-
dride, and acetyl chloride were also obtained from Wako. BSTFA +
TMCS (99 : 1, v/v, 100 µL)were purchased from Supelco (Bellefonte,
USA). n-Propyl acetate, methanol, pyridine, and heptane were pur-
chased from Kanto Chemical Co., Inc. (Tokyo, Japan). Concentrated
sulfuric acid was purchased from Nacalai Tesque, Inc. (Kyoto,
Japan). The standard of creatinine was purchased from Katayama
Chemical, Inc. (Osaka, Japan). The deuterated internal standard
(IS), creatinine-d3, was obtained from Funakoshi Co., Ltd. (Tokyo,
Japan). Amicon Ultra - 4 centrifugal filter units were purchased
from Merck KGaA (Darmstadt, Germany).
Analysis of p-cresol
Preparation of case samples
Blood, urine, and organ samples were prepared according to the
following methods. A 0.1-mL aliquot of sample blood and 0.9 mL of
distilled water were mixed. A 0.01-mL aliquot of sample urine and
0.99 mL of distilled water were mixed. A 0.1-g sample of organ
tissue was homogenized in a bead crusher with 1 mL of distilled
water.
Pretreatment before extraction
An outline of the procedure used is showed in Figure 1.
“Free p -cresol” is non-protein-bound and unconjugated p -cresol
(F p -cresol). “Conjugated p -cresol” is non-protein-binding conju-
gated p -cresol (C p -cresol). “Total p -cresol” includes free p -cresol,
protein-bound conjugated p -cresol, and conjugated p -cresol.
F p-cresol
The solution was added to the centrifugal filter unit. After cen-
trifugation at 3500 rpm for 60 min, all of the blood and urine filtrates
were added to a glass test tube. Regarding tissues, 0.5 mL of the
filtrate and 0.5 mL of distilled water were added to the glass test
tube.
F and C p-cresol
The solution was added to the centrifugal filter unit. After cen-
trifugation at 3500 rpm for 60 min, all of the blood and urine filtrates
with 0.1 mL of concentrated sulfuric acid were added to a glass test
tube. Regarding tissues, 0.5 mL of the filtrate, 0.5 mL of distilled
water, and 0.1 mL of concentrated sulfuric acid were added to the
glass test tube. The tube was immediately sealed, and after thor-
ough mixing, was incubated at 90C for 30 min. After heating, the
solution was allowed to cool to room temperature.
Total p-cresol
The solution and 0.1 mL of concentrated sulfuric acid were
added to a glass test tube. Regarding organ samples, 0.5 mL of
distilled water, 0.1 mL of concentrated sulfuric acid, and 0.5 mL of
the homogenized sample was added to a glass test tube. The tube
was immediately sealed, and after thorough mixing, was incubated
at 90C for 30 min. After heating, the solution was allowed to cool to
room temperature.
Extraction
Two milliliters of ethyl acetate, 1 mL of n-propyl acetate, IS
solution (p -cresol -d8, 1 µg), and 0.5 g NaCl were added to the
sample, followed by thorough mixing. After centrifugation at 3000
rpm for 5 min, the organic layer was transferred into another glass
test tube and 0.2 g MgSO4 and 0.1 g NaCl were added. After
thorough mixing and centrifugation at 3000 rpm for 1 min, the
organic layer was transferred to another glass test tube, and evapo-
rated to just short of dryness under nitrogen. The sample was
heatedusing a microwave at 500W for 30 sec, and 100 µl of BSTFA +
TMCS (99 : 1, v/v) was immediately added to the tube. The test
tube was sealed and heated using a microwave at 500 W for 90 sec
twice (microwave-accelerated derivatization of p -cresol). The
solution was placed in an autosampler vial for a GC-MS analysis.
Extraction of creatinine
A 0.01-mL aliquot of sample urine, 2 mL of methanol, and IS
solution (creatinine-d3, 10 μg) were added to a glass test tube.
After mixing, the solution was evaporated to dryness under nitro-
gen. A total of 0.1 mL of ethyl acetate, 0.01 mL of pyridine, 0.05 mL of
acetic anhydride, and 0.01 mL of acetyl chloride were added in this
order to the sample, followed by thorough mixing. The test tube
was sealed and heated using a microwave at 500 W for 30 sec six
times (microwave-accelerated derivatization of creatinine). A total
of 0.05 mL of heptane was added to the sample. After mixing and
centrifugation, the supernatant was placed in a vial for a GC-MS
analysis.
Chromatographyconditions
The GC-EI-MS/MS system was GCMS-TQ8030 (Shimadzu,
Kyoto, Japan). The column used was ZB SemiVolatiles (2 m × 0.18
mm i.d., film thickness of 0.5 µm, Phenomenex, USA)/BPX5 (4 m ×
0.15 mm i.d., film thickness of 0.25 µm, SGE Analytical Science,
Australia).
Electron ionization was employed at a voltage of 70 eV. The
carrier gas was helium delivered at a constant flow of 2.9 mL/min.
The oven temperature was initially 40C for 0.5 min, increased to
200C at 70C/min, increased to 290C at 50C/min, and held for 4
min. The injection, interface, and ion source temperatures were all
set to 280C. The sample was injected in the split mode (1 : 10).
Regarding p-cresol, Multiple Reaction Monitoring (MRM) transi-
tions and collision energies were assessed through injections of
individual standards. The precursor ions, product ions, and colli-
sion energies for p -cresol -TMS and p -cresol -d8-TMS were m/z
165.0 to 91.1 (9V) and m/z 172.0 to 98.2 (9V), respectively.
Fig.1 Flow chart of p -cresol extraction and fractionation
Figure 1 shows p -cresol extraction in the present study by a flow chart.
The sample is separated with a filter with a molecular weight of 3 kDa.
When the filtrate is analyzed, free p -cresol is obtained.When the filtrate
is treated by heat and acid, non-protein bound p -cresol is analyzed.
Total p-cresol is obtained when the original sample is treated by heat
and acid without filtering.
82 N. Ikematsu, et al. Organ distribution of p-cresol in HD patients
The concentration of creatinine was quantified in the SIM mode.
The selected ions for creatinine-2AC (acetyl) and creatinine-d3-2
Ac were m/z 113.0 and m/z 158.0, respectively.
Quantitative analysis
Calibration curves were constructed by plotting the peak area
ratios of p -cresol to p -cresol -d8 (1 µg). Regarding blood and urine
samples, the internal standard method was employed. A calibration
curve was constructed after the analysis of control blood/urine
spiked with 5 known amounts of p -cresol. Regarding organ sam-
ples, the standard addition method for calibration was employed. In
order to make a calibration curve for each organ, 4 amounts of p -
cresol and p -cresol -d8 at a constant concentration were spiked into
0.1-g tissue samples.
The concentration of creatinine was calculated from the peak
area ratios of creatinine to creatinine-d3 (10 µg).
Ethics
This study obtained and executed approval by the Ethics Commit-
tee on Medical Studies in Fukuoka University (2017M007).
RESULTS
The concentrations of total p -cresol and its 3 fractions : F, C, and
protein-binding conjugated (PC) p -cresol, were summarized in
Table 2. The urinary p -cresol concentration was corrected by the
urinary creatinine (Cr) concentration.
Only a small total p -cresol concentration was detected in non-
HD cases. In HD cases, total p -cresol concentrations in the blood,
lungs, liver, kidneys, and urine were 11.92, 9.99, 4.82, 13.08 µg/
mL or µg/g, and 79.73 ng/mL, respectively. Blood p -cresol con-
centrations were 30-fold higher than those in non-HD cases.
Urinary p -cresol/Cr concentrations were also markedly higher in
HD cases than in non-HD cases (4.79 ng/mL). p -Cresol concentra-
tions in the organs were also significantly higher in HD cases
than in non-HD cases ; p -cresol concentrations were 20-fold higher
in the lungs and liver and 40-fold higher in the kidneys.
p -Cresol concentrations and percentages of F, PC, and C p -
cresol were shown in pie charts (Fig. 2). In HD cases, the percent-
ages of C and PC urinary p -cresol were 57 and 41%, respec-
tively. C p -cresol was 66% and PC p -cresol was 25% in the kidneys.
In blood, p -cresol was mainly present as PC p -cresol (63%). In the
liver, F p -cresol was the main component of p -cresol (54%). The
composition of p -cresol in the lungs was very similar to that in the
kidneys.
DISCUSSION
In the present study, we investigated an analytical method for p -
cresol not only in blood and urine, but also in organs. We also
attempted to reveal the organ distribution of p -cresol and its me-
tabolites.
Table2 Distribution of p -cresol in blood, urine, and organs
p-Cresolconcentrations




































The reference value of non-HD cases is described in the parentheses.
ap -cresol concentration/Cr
Unit ; µg/ml for blood ; µg/g for organs, andng/ml forurine
Dataareshownasmeansstandarderror.
Fig.2 Pie chart of the distribution of p -cresol in blood, urine, and organs
Free p -cresol
protein -binding conjugated p -cresol
conjugated p -cresol
† urine : p -cresol/Cr
Figure 2 shows the p -cresol concentrations in blood, urine, and organs from Table 2. The total concentration is shown by the size of the circle, and the
percentage of each concentration of F, PC, and C p -cresol is expressed in the pie chart.
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Measurement of p-cresol fractions : F, C, and PC p-cresol
In the human body, p -cresol is synthesized in the large intestine
by intestinal bacteria (1-4). It is then absorbed by the intestinal
wall, conjugated, and transported in the blood via the portal vein. (5-
8). Following intestinal absorption, it is also conjugated and me-
tabolized in the liver after general circulation and excreted in the
urine. Recent studies reported a close relationship between the
kidneys and gastrointestinal (GI) tract- frequently referred to as
the kidney-gut axis- in patients with chronic kidney disease (CKD).
Numerous molecules, which are either excreted or metabolized by
the kidneys, accumulate in patients with CKD (20-23).
p -Cresol exists in various forms in blood, urine, and organs,
namely, F, C, and PC p -cresol. We attempted to analyze the concen-
trations of p -cresol and its metabolites in the organs of HD patients
using heat and acid treatments and GC-MS (8, 15).
p -Cresol concentrations in uremic serum have been assessed
using colorimetric nitroaniline diazotization (14), HPLC (7, 24),
gas chromatography (GC) (13), and gas chromatography/mass
spectrometry (GC/MS) (8, 15). We analyzed p -cresol concentra-
tions using the method described by H. de Loor et al. (8). In their
study, most p -cresol was in its sulfated form, more than 95%, and a
small proportion was glucuronidated, less than 5%, in serum. They
described also that this method, acid and heat deproteinization, can
convert almost all of p -cresylsulfate into p -cresol present in the
serum. We analyzed F, C, and PC p -cresol individually by their
method.
Distributionofp-cresol inblood,urine,andorgans
Total blood p -cresol concentrations were approximately 30- fold
higher in HD cases than in non-HD cases. This result was consis-
tent with previous findings showing that the blood concentrations
of cresol and these sulfates were significantly higher in HD patients
than non-HD individuals (8, 13, 14). Total p -cresol concentrations in
urine, corrected by the urinary Cr of HD cases, were also approxi-
mately 16- fold higher than in non-HD cases. The liver, kidneys,
and lungs were examined as target organs. p -Cresol concentrations
in the kidneys were approximately 40- fold higher in HD cases
than in non-HD cases. p -Cresol concentrations were also signifi-
cantly higher, by approximately 20- fold, in the liver. Therefore, p -
cresol appears to accumulate in the organs of HD patients be-
cause of compromised excretion from the kidneys. Two of the 4
HD cases had a HD duration of less than 6 months (Table 1).
These 2 patients had a higher concentration of blood p -cresol than
the others (Table 3). In both of these cases, the deceased did not
like going to the doctor, so treatment was not started until there
was a risk for death. Therefore, the blood p -cresol concentration in
these cases might reflect the stage of CKD (25) rather than the
duration of HD.
Percentages of F, C, and PC p-cresol in blood, urine, and organs
In non-HD cases, the percentage of each p -cresol type in the
blood was as follows : 81% as PC, 8% as C, and 11% as F p -cresol.
This composition was markedly different in the liver : F p -cresol
was 44%, PC p -cresol was 31%, and C p -cresol was 25%. F p -cresol is
absorbed, partly conjugated to C p -cresol in the intestinal wall,
and is transported to the liver by the portal vein (5-8). Therefore,
the percentage of F p -cresol is higher than in the blood. F and PC p -
cresol are the main forms in the kidneys and liver, which differs
from that in the blood. In urine, p -cresol was excreted as 59% of C,
33% of PC, and 8% of F p -cresol. Therefore, metabolized p -cresol
was mainly excreted. The percentages of PC p -cresol in the lungs
and kidneys were similar at 49 and 46%, respectively, whereas
those of C p -cresol markedly differed at 28 and 12%, respectively.
Since C p -cresol is excreted in the urine, the percentage of C p -
cresol may be lower in the kidneys than in the lungs.
We investigated the percentages of F, C, and PC p -cresol in HD
and non-HD cases. In the urine, no significant differences were
observed between HD and non-HD cases, and the percentages of C
and PC p -cresol in HD cases were 57 and 41%, respectively. p -
Cresol is excreted into urine as conjugated p -cresol ; however, the
volume of urine generated by HD patients is decreased. While the
composition of conjugated p -cresol in the urine did not signifi-
cantly change, conjugated p -cresol accumulated in the body, and
was distributed in various organs. Thus, the composition of p -
cresol in HD cases markedly differed from non-HD cases, except in
urine : for example, the percentages of C and PC p -cresol in the
kidneys of HD cases were 66 and 25%, respectively. This high
percentage of C p -cresol in various organs was a significant
difference between HD and non-HD cases. The percentage of PC p -
cresol in blood, 63%, was markedly higher than that in other organs
and urine. Accumulated C p -cresol may stably bind to proteins in
blood. The composition of p -cresol in the lungs was very similar to
that in the kidneys. Therefore, the lungs reflected the composi-
tion of p -cresol in the kidneys. In the liver, the composition of p -
cresol was similar between HD and non-HD cases. In HD pa-
tients, p -cresol also accumulated in the liver, but the normal
functioning liver might conjugate and bind p -cresol almost at the
same ratio in non-HD patients. C p -cresol concentrations have
been shown to positively correlate not only with CKD, but also
cardiovascular disease (CVD) mortality (25). We investigated C p -
cresol concentrations in HD cases. C p -cresol accounted for only
16% of total p -cresol in the liver with much higher percentages in
the blood, urine, and other organs, especially as high as 65% in the
lungs and kidneys. High C p -cresol concentrations in HD patients
may induce CVD. Free p -cresyl sulfate is associated with vascular
calcification and is a predictor of overall and CVD mortality in CKD
patients (25). In the present study, we also confirmed higher C p -
cresol concentrations in HD cases than in non-HD cases, and that
vascular damage was present in all HD cases. High-grade arterio-
sclerosis was observed in the thoraco-abdominal aorta of all HD
cases. All HD cases showed sclerosis or stenosis of the coronary
and basilar arteries. Two of the 4 HD cases also had a history of
myocardial infarction (MI) and coronary artery bypass grafting
(CABG) (Table 3). The results of the present study confirm previ-
ous studies, that a high concentration of C p -cresol might be
related to CVD in HD cases.
The removal of p -cresol from the body is important for reducing
CKD and CVDmortality (25). p -Cresol cannot be removed by HD
because it binds to proteins in the blood (24). The present results
revealed that 60% of p -cresol existed as PC p -cresol in the blood.
Heat and acid treatments are needed in order to separate the PC
and C p -cresol forms. Therefore, difficulties are associated with
removing p -cresol that accumulates in the blood and organs from
the body. Another strategy is to control the production and absorp-
tion of p -cresol in the intestines.
CONCLUSION
p -Cresol concentrations are high in the blood of HD patients.
However, its distribution in the body has not yet been investigated in
detail. We herein reported the distribution of p -cresol in HD
patients.
In the present study, p -cresol concentrations were markedly
increased not only in the blood, but also the urine and organs of HD
cases. The percentages of C and PC urinary p -cresol were 57 and
41%, respectively. C p -cresol was 66% and PC was 25% in the
kidneys. The composition of p -cresol in the lungs was very similar to
that in the kidneys. The composition of p -cresol, namely, F, C, and
PC p -cresol, markedly differed between HD and non-HD cases. A
high concentration of p -cresol and high percentage of C p -cresol
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may induce CVD.
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Table3 Blood Concentration of p -cresol and cardiovascular damage in HD cases
Blood p-Cresol concentrations Cardiovascular damage
Cases Free Conjugated Protein binding-conjugated Total AS CS BS MI/CABG
HD-1 0.59 7.75 10.46 18.80 +++ ++  
HD-2 0.08 3.36 5.21 8.65 +++ +++ +++ 
HD-3 0.22 4.34 7.45 12.01 +++ +++ +++ 
HD-4 0.07 1.41 6.74 8.22 +++ +++ ++ 
Abbreviations : HD, hemodialysis ; AS, arteriosclerosis in the thoraco-abdominal aorta ; CS, arteriosclerosis or stenosis in the coronary artery ; BS,
arteriosclerosis in the basilar artery ; MI, myocardial infarction ; CABG, coronary artery bypass grafting
Unit : µg/ml for concentration
AS and BS, + mild ;++ medium ;+++ severe
CS, + sclerosis ; ++ stenosis50% ; +++ stenosis50%
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